MedTrace Logo

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

NCT03821857 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2025-11-24

No results posted yet for this study

Summary

The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

Conditions

  • Alzheimer Disease

Interventions

DRUG

18-F-Flortaucipir

Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Kejal Kantarci, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-27
Primary Completion
2030-05-31
Completion
2030-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821857 on ClinicalTrials.gov